Psychedelic Science Newsletter
Issue #63November 9, 20267 studies

A 9-minute psychedelic cut depression scores by 15 points in a single-dose trial

Psychedelic and ketamine research had a genuinely strange week — one drug worked faster than almost anyone expected, and another's most-cited effects in mice turned out to be surprisingly hard to reproduce.

Here's what the evidence actually showed.

🐸 Toad Venom, 9 Minutes, and a 57% Remission Rate

  • 5-MeO-DMT — the primary psychoactive compound in Sonoran Desert toad secretion — was tested as an inhaled treatment for treatment-resistant depression in a phase 2b trial. The active drug produced a 15.5-point drop in depression scores versus placebo by day 8, with 57.5% of patients in remission compared to 0% on placebo.
  • The median psychoactive window lasted 9–14 minutes depending on dose, and 97.5% of patients were ready for discharge within one hour — a dramatically shorter session than psilocybin or MDMA protocols.
  • The catch: nearly all the remission data comes from a single randomized trial, no protocol-mandated therapy was included, and the compound's receptor profile is genuinely unusual — it binds serotonin receptors with a roughly 30- to 300-fold preference for one subtype over the one most psychedelics target.

Why it matters: If the results replicate in larger phase 3 studies, a sub-hour, therapy-optional session model would represent a meaningfully different clinical format than anything currently approved.

🔗 CNS drugs Review 🗓️ Nov 4

Key Findings

🍄 Psilocybin's Persistent Effects in Mice Were Surprisingly Hard to Pin Down

  • Five independent labs ran the same psilocybin experiment on roughly 200 mice each and found consistent acute results: more anxiety-like behavior and reduced fear expression right after dosing.
  • The persistent effects — reduced anxiety and depression-like behavior 24 hours later, improved fear extinction, social reward changes — did not replicate reliably across labs, suggesting those reported effects may be modest or inconsistent in this animal model.
💡 Acute psilocybin effects in mice held up; the lasting ones largely didn't.
🥇 Top 1% journal 🔗 Nature neuroscience Journal Article 🗓️ Nov 2

🧠 Psilocybin May Shift Brain Chemistry Through Astrocytes, Not Just Neurons

  • A study in rodents found that psilocybin reduced inhibitory signaling in the brain's reward center by lowering GABA levels specifically inside astrocytes — the support cells of the brain — rather than in neurons directly.
  • The mechanism involved changes in astrocyte gene activity linked to a GABA-metabolizing enzyme, triggered upstream by serotonin receptor signaling. This adds a non-neuronal layer to how psilocybin may work.
💡 Psilocybin's reward-circuit effects may run through brain support cells, not just neurons.
🥈 Top 2% journal 🔗 Experimental & molecular medicine Journal Article 🗓️ Nov 5

💊 MDMA-Assisted Therapy Tested for Social Anxiety in a Randomized Trial

  • A randomized, open-label, wait-list controlled trial evaluated MDMA-assisted therapy for social anxiety disorder, building on a prior placebo-controlled study that showed promise for the same indication.
  • MDMA's known effects on socio-emotional processing make it a mechanistically plausible candidate for social anxiety, though the open-label design limits how firmly conclusions can be drawn from this trial.
💡 MDMA therapy for social anxiety moved into randomized testing — open-label for now.
🥉 Top 5% journal 🔗 Journal of affective disorders Journal Article 🗓️ Nov 6

⚡ Combining Brain Stimulation With Ketamine May Extend Its Short Window

  • Ketamine's antidepressant effects in treatment-resistant depression typically fade within days. A preliminary double-blind trial tested whether intermittent theta-burst stimulation — a form of non-invasive brain stimulation — applied after ketamine could extend that response.
  • The study also examined whether any sustained benefit was associated with changes in large-scale brain network activity, though results are described as preliminary.
💡 Brain stimulation after ketamine is a plausible extension strategy, still early-stage.
🔗 Psychiatry and clinical neurosciences Journal Article 🗓️ Nov 5

🌿 Syrian Rue and Ayahuasca Vine Evolved the Same Molecules Independently

  • A genomics and enzyme study found that Syrian rue and the ayahuasca vine — plants separated by over 100 million years of evolution on different continents — independently evolved the same class of neuroactive compounds called harmala alkaloids, which inhibit a key enzyme involved in breaking down serotonin and related molecules.
  • The convergence happened through independent duplication of an ancestral enzyme from serotonin biosynthesis, a finding the researchers describe as convergent evolution at the levels of enzymes, pathways, and genomes.
💡 Two unrelated plants reinvented the same psychoactive chemistry on separate continents.

🔬 The Receptor Signal That Was Supposed to Explain Hallucinations Is Disputed

  • Two papers this week clashed over whether activation of inhibitory G proteins — a specific molecular signaling pathway — reliably distinguishes hallucinogenic from non-hallucinogenic serotonin receptor agonists.
  • One study using human post-mortem brain tissue found that hallucinogens activated both a canonical and an inhibitory protein pathway, while non-hallucinogens activated only the canonical one. A separate paper reanalyzed the original source data behind this claim and argued the inhibitory pathway is less predictive than the canonical signals.
💡 The molecular signature of hallucination remains genuinely contested between two research groups.
🔗 Neurochemistry international Journal Article 🗓️ Nov 6

Implications

The week's sharpest tension sits between clinical speed and mechanistic clarity. A 9-minute treatment is showing remission rates that demand attention, while the basic science — what psilocybin actually does in the brain, which receptor signals produce hallucinations, whether mouse models predict human outcomes — remains actively contested among researchers.

Studies in this issue

Primary sources used for this newsletter.

  1. Psilocybin's effects on mouse behavior across multiple research centers
    key findingNature neuroscience2026-11-02PMID 42972049
  2. Psilocybin changes reward system activity by affecting support cell gene activity
    key findingExperimental & molecular medicine2026-11-05PMID 42988866
  3. Harmala Alkaloids Evolved Separately in Syrian Rue and Ayahuasca Plants
    key findingbioRxiv : the preprint server for biology2026-11-06PMID 42990209